The development of in vivo Aβ and tau biomarkers has greatly facilitated diagnosing AD [2]; however, a reliable prognosis of AD-related cognitive decline in clinical settings remains a critical yet unmet challenge. The gene discussed is MAPT; the disease is Mental deterioration.